HFSA/ACC/AHA release statement on continued use RAASi during COVID-19 outbreak
The Heart Failure Society of America (HFSA), ACC, and AHA released a joint statement recommending continued use of renin angiotensin aldosterone system (RAAS) antagonists, including ACEi and ARBs, during the COVID-19 outbreak. Earlier, the ESC released a similar statement recommending continued use of ACE and ARBs. The recommendation of the HFSA, ACC, and AHA is based on the lack of experimental or clinical data demonstrating beneficial or adverse outcomes with ACEi or ARBs use among COVID-19 patients using these agents.
The recommendation concerns those patients who are currently prescribed ACEi, ARBs or other RAAS antagonists for indications for which these agents are known to be beneficial, such as heart failure, hypertension, or ischemic heart disease. If patients with CVD are diagnosed with COVID-19, individualized treatment decisions should be made according to each patient’s hemodynamic status and clinical presentation. It is advised that any RAAS-related treatments of patients should not be added or removed beyond actions based on standard clinical practice.
The HFSA, ACC, and AHA stress the importance of urgent and more detailed research guiding to optimal care for people with CVD and who may contract COVID-19. Recommendations are updated according to further research findings related to CV health in COVID-19.